A New Era for Liver Health in Canada
In 2026, Health Canada has officially approved Resmetirom (Rezdiffra), the first oral medication specifically designed to treat Metabolic Dysfunction-Associated Steatohepatitis (MASH) with liver fibrosis. This liver-directed thyroid hormone receptor-beta agonist works by increasing hepatic fat metabolism and reducing lipotoxicity. For Canadians with MASLD that has progressed to MASH, this provides a critical medical intervention alongside lifestyle changes. Approval is a major milestone for the Canadian Liver Foundation, as it offers a way to potentially reverse fibrosis and prevent the progression to cirrhosis and liver failure.
The THR-β Mechanism
Resmetirom specifically targets the thyroid hormone receptor-beta (THR-β) in the liver, while avoiding the alpha receptors in the heart and bone. This selectivity ensures that liver fat is burned without causing systemic side effects like tachycardia. Clinical data from the MAESTRO-NASH trials demonstrated significant MASH resolution and fibrosis improvement. For Canadian clinicians, this medication is now integrated into the 2026 MASLD/MASH management algorithms.
Measuring Fibrosis Regression
The success of MASH treatment is often measured by the reduction in liver stiffness (kPa) via FibroScan.
Stiffness-Volume Ratio
In this clinical context, $E$ represents Young's modulus (stiffness). A decreasing trend in kPa over 12 months on Resmetirom validates the drug's anti-fibrotic effect. Strategic Advice: If your FIB-4 score is above 1.3, request a FibroScan to determine if you are a candidate for this new therapy. Be aware that private insurance in Canada (e.g., Sun Life, Manulife) may require specific fibrosis staging (F2-F3) for coverage. Combining Resmetirom with a low-fructose Mediterranean diet will maximize liver fat clearance and optimize your overall metabolic health.